Skip to main content

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Latest News

Eurozone, ECB - ECB Logo at Night
Beyond the GRANOLAS: JPMorgan Picks 3 Top Stocks to Bet on Europe
Barchart - Sat Mar 2, 8:30AM CST
Barchart
Sat Mar 2, 8:30AM CST
The renowned brokerage firm weighed in on its top stock picks from the European market, which could offer investors better value than the outsized GRANOLAS group of equities at current levels.
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Motley Fool - Fri Feb 16, 6:15AM CST
Motley Fool
Fri Feb 16, 6:15AM CST
Don't count these companies out too soon.
Sanofi (SNY) Q4 2023 Earnings Call Transcript
Motley Fool - Thu Feb 1, 2:15PM CST
Motley Fool
Thu Feb 1, 2:15PM CST
SNY earnings call for the period ending December 31, 2023.
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
Motley Fool - Sun Dec 17, 2023
Motley Fool
Sun Dec 17, 2023
You can pick these players up for a great price right now.
3 Stocks to Buy Before 2024 That Can Set You Up For Life
Motley Fool - Thu Dec 14, 2023
Motley Fool
Thu Dec 14, 2023
These stocks are still relatively cheap, but don't expect them to stay that way for long.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Motley Fool - Thu Nov 30, 2023
Motley Fool
Thu Nov 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Informatica soars on its AI-powered data management cloud growth
MarketBeat - Sun Nov 12, 2023
MarketBeat
Sun Nov 12, 2023
Enterprise cloud data management software provider Informatica Co. (NASDAQ: INFA) saw its shares surge 23% on its impressive Q3 2023 earnings report. The compa
MarketBeat Week in Review – 11/6 - 11/10
MarketBeat - Sat Nov 11, 2023
MarketBeat
Sat Nov 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time
AllPennyStocks.com - Tue Nov 7, 2023
AllPennyStocks.com
Tue Nov 7, 2023
There are very good reasons that stocks generally gain in value after a company receives orphan drug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36% after the announcement of an orphan designation. The impact was...
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time
Yolowire - Tue Nov 7, 2023
Yolowire
Tue Nov 7, 2023
There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36%...
Pfizer and Sanofi shares fall, which one to scoop up?
MarketBeat - Tue Nov 7, 2023
MarketBeat
Tue Nov 7, 2023
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows
This Stock Just Dropped By 15%: Is It a Buy?
Motley Fool - Fri Nov 3, 2023
Motley Fool
Fri Nov 3, 2023
Now could be a great opportunity to buy low.
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Investor Brand Network - Wed Nov 1, 2023
Investor Brand Network
Wed Nov 1, 2023
NetworkNewsWire Editorial Coverage : GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional weight-loss procedures. There is a...
Investor patience tested as pharmaceutical stocks take a tumble
MarketBeat - Wed Nov 1, 2023
MarketBeat
Wed Nov 1, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
This High-Yielding ETF Gives Investors Great Exposure to European Stocks
Baystreet - Mon Oct 30, 2023
Baystreet
Mon Oct 30, 2023
If you’re looking for a top exchange-traded fund (ETF) to hold in your portfolio and which can ...
Sanofi (SNY) Q3 2023 Earnings Call Transcript
Motley Fool - Fri Oct 27, 2023
Motley Fool
Fri Oct 27, 2023
SNY earnings call for the period ending September 30, 2023.
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
Motley Fool - Mon Oct 16, 2023
Motley Fool
Mon Oct 16, 2023
These two large-cap biopharma companies could have more room to run.
2 Surefire Stocks That Could Make You Richer
Motley Fool - Wed Oct 11, 2023
Motley Fool
Wed Oct 11, 2023
It won't happen overnight, but with these stocks, a little patience is all you need.
Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
PR Newswire - Tue Oct 10, 2023
PR Newswire
Tue Oct 10, 2023
/PRNewswire/ -- The Harris Poll, a Stagwell (NASDAQ: STGW) agency, announced today the findings from a first-of-its-kind global hemophilia survey – 'Hemophilia...
Why Shares of Kymera Therapeutics Jumped on Tuesday
Motley Fool - Tue Oct 3, 2023
Motley Fool
Tue Oct 3, 2023
The company had a big bounce after hitting a 52-week low the day before.
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
Motley Fool - Sat Sep 30, 2023
Motley Fool
Sat Sep 30, 2023
If the biotech does split its stock, it will be a first for the company.
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
Motley Fool - Thu Sep 14, 2023
Motley Fool
Thu Sep 14, 2023
This market is currently in its infancy.
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
PR Newswire - Wed Sep 13, 2023
PR Newswire
Wed Sep 13, 2023
/PRNewswire/ -- In collaboration with Ice-T, Sanofi has debuted a trailer for this year's newest thriller – The Season. The trailer taps into suspenseful movie...
Could This Medicine Be the Next Winner for Novartis?
Motley Fool - Wed Aug 23, 2023
Motley Fool
Wed Aug 23, 2023
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
Motley Fool - Mon Aug 21, 2023
Motley Fool
Mon Aug 21, 2023
The biotech's focus on innovation could be a boon for shareholders.